Biologics and Biosimilars
Science and Market
Biologics are large, complex molecules derived from living cells (bacteria, yeast, mammalian cells) rather than chemical synthesis. They include monoclonal antibodies, vaccines, recombinant proteins, and gene therapies. Biosimilars are approved copies of reference biologic drugs whose patents have expired, demonstrated to be highly similar in structure, efficacy, and safety.
- Biologics are the fastest-growing segment of the global pharmaceutical market (estimated $500 billion by 2030), driven by treatments for cancer, rheumatoid arthritis, diabetes (insulin analogues), and rare genetic disorders.
- Unlike small-molecule generics (identical copies), biosimilars require extensive clinical testing to demonstrate similarity because slight differences in manufacturing can affect therapeutic outcomes — hence their approval pathway is more rigorous and expensive than standard generic drugs.
- India's biosimilars market is projected to grow from $184 million in 2026 to $1.02 billion by 2035 (CAGR ~21%), driven by patent expirations of major biologics and government incentives.
- Monoclonal antibodies (mAbs) account for ~55% of India's biosimilars market; major products include trastuzumab (breast cancer), bevacizumab (colorectal cancer), adalimumab (autoimmune), and rituximab (lymphoma).
- Indian companies with significant biologics capability include Biocon, Dr. Reddy's, Zydus, Reliance Life Sciences, and Intas Biologicals.
● Tracked since February 01, 2026 · last seen March 20, 2026 · updates as the daily brief publishes
See it in today’s brief.
Daily current affairs with every static concept explained in place.
Read the daily brief